Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for percutaneous image-guided breast biopsy, effective May 15, 2026. Here's what billing teams need to know before that date.
CMS updated its percutaneous image-guided breast biopsy coverage policy with a May 15, 2026 effective date. The policy governs how Medicare covers minimally invasive breast biopsy procedures performed under imaging guidance — including ultrasound, stereotactic, and MRI-guided approaches. The actual policy document does not list specific CPT or HCPCS codes in the data provided, so your first step is pulling the full policy from CMS and confirming which codes apply to your procedure mix.
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Percutaneous Image-Guided Breast Biopsy |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Radiology, Breast Surgery, Interventional Radiology, Oncology |
| Key Action | Pull the full updated policy from CMS before May 15, 2026 and audit your charge capture against revised medical necessity criteria |
CMS Percutaneous Image-Guided Breast Biopsy Coverage Criteria and Medical Necessity Requirements 2026
The CMS percutaneous image-guided breast biopsy coverage policy governs Medicare reimbursement for needle biopsy procedures performed under real-time imaging — most commonly ultrasound, stereotactic X-ray, or MRI guidance. These are high-volume procedures in radiology and breast surgery practices, which makes any coverage policy modification a billing priority, not a background issue.
When CMS modifies a policy like this, the changes typically touch medical necessity criteria, documentation requirements, or the indications list. Any one of those shifts can turn previously clean claims into denials. The real risk for your billing team is submitting claims under old criteria after May 15, 2026, when the new rules are already in effect.
Because the specific policy document was not available in the data provided here, the exact revised criteria are not reproduced below. What that means for you: do not rely on this post alone. Pull the full updated policy directly from CMS before May 14, 2026, and compare it line by line against what your team is currently billing.
Medical necessity documentation is the core driver of claim denial for image-guided biopsy procedures. CMS and its Medicare Administrative Contractors look for documentation showing the imaging modality was appropriate for the lesion type, that the biopsy was performed because of a suspicious finding, and that the clinical record supports the procedure before authorization. If your documentation templates haven't been updated to reflect the revised coverage policy criteria, your denial rate will tell you about it after the fact.
Prior authorization requirements for percutaneous breast biopsy under Medicare have historically been limited, but the 2026 modification may affect how MAC-level contractors interpret medical necessity on pre-claim review. If your practice sees a significant volume of Medicare breast biopsy procedures, check with your MAC directly to understand whether any pre-authorization or advanced beneficiary notice requirements apply after the effective date.
CMS Percutaneous Image-Guided Breast Biopsy Exclusions and Non-Covered Indications
The policy document data provided does not include a specific exclusions list for this modification. That said, standard CMS coverage policy patterns for breast biopsy procedures typically exclude the following categories, and your billing team should verify these against the full updated policy text:
Procedures performed without an appropriate imaging finding to justify the biopsy are routinely denied on medical necessity grounds. CMS expects the clinical record to document a suspicious or indeterminate lesion — not just a screening finding — before a percutaneous biopsy is covered. Repeat biopsies of the same site without new clinical indication are another common non-covered scenario.
Experimental or investigational biopsy techniques fall outside standard coverage. If your practice uses newer guidance modalities or device-assisted biopsy systems not yet recognized in CMS billing guidelines, those claims carry higher denial risk. Check the updated policy text specifically for any language about guidance modality coverage before May 15, 2026.
Coverage Indications at a Glance
The policy data provided does not include a detailed, indication-level breakdown for this modification. The table below reflects standard CMS coverage patterns for image-guided breast biopsy. Verify each row against the full updated policy text before using this for billing decisions.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Ultrasound-guided percutaneous breast biopsy for suspicious or indeterminate lesion | Typically Covered | Verify with CMS policy | Medical necessity documentation required |
| Stereotactic-guided percutaneous breast biopsy | Typically Covered | Verify with CMS policy | Must document appropriate lesion and imaging modality selection |
| MRI-guided percutaneous breast biopsy | Typically Covered | Verify with CMS policy | MRI guidance indication must be documented; not first-line for lesions visible on ultrasound |
| Biopsy without documented imaging finding | Not Covered | N/A | Fails medical necessity criteria |
| Repeat biopsy without new clinical indication | Not Covered | N/A | Prior biopsy results and new clinical rationale required |
| Experimental guidance modalities | Coverage Unconfirmed | Verify with CMS policy | Review updated policy text for modality-specific language |
CMS Percutaneous Image-Guided Breast Biopsy Billing Guidelines and Action Items 2026
This is where most billing teams lose money on a policy modification — they know a change happened but don't translate it into specific workflow updates before the effective date. Here's what to do right now.
| # | Action Item |
|---|---|
| 1 | Pull the full updated CMS policy before May 14, 2026. The effective date is May 15, 2026. You need the actual policy text in hand before that date — not on that date. Go to the CMS coverage database and download the current version of the percutaneous image-guided breast biopsy policy. The source URL is: https://app.payerpolicy.org/p/cms/272-v1. |
| 2 | Run a line-by-line comparison against the prior version. The change type on this policy is "Modified," not "New." That means something specific changed from the previous version. Find it. Changes to medical necessity criteria, documentation language, or covered indications are the most financially significant. If you don't have the prior version on file, request it from your MAC or pull it from the CMS website archives. |
| 3 | Audit your documentation templates against the revised criteria. Once you know what changed, update your documentation templates before May 15, 2026. If the revised policy adds a documentation requirement — say, requiring the interpreting physician to specify why a particular imaging modality was selected — your templates need to capture that before the first post-effective-date claim goes out. |
| 4 | Check with your MAC for any local coverage determination overlap. CMS national coverage policy sets the floor, but your Medicare Administrative Contractor may have a local coverage determination that adds requirements for percutaneous image-guided breast biopsy billing in your region. Contact your MAC directly and ask whether this 2026 CMS modification triggers any changes to your local policies or pre-claim review requirements. |
| 5 | Update your charge capture and coder education before the effective date. Your coders need to know what changed. Run a brief internal update — even a one-page summary — before May 15, 2026. Focus on any changed indication criteria, any added or removed covered modalities, and any documentation changes. A coder selecting the wrong modifier or missing a required diagnosis code after the effective date creates a denial pattern that takes months to unwind. |
| 6 | Flag this for your compliance officer if your practice has high Medicare breast biopsy volume. Coverage policy modifications that touch medical necessity criteria carry compliance risk, not just billing risk. If a significant portion of your breast biopsy procedures are billed to Medicare, loop in your compliance officer before May 15, 2026. They should review the revised criteria against your current documentation practices and sign off on any template changes. |
| 7 | Watch for claim denial patterns starting in late May 2026. Even if you do everything right, the first few weeks after a coverage policy change often produce denials from automated edits that haven't been communicated clearly. Set a watch on your denial queue for image-guided breast biopsy claims starting the week of May 19, 2026. If denials spike, identify the denial reason code immediately and trace it back to the specific criteria change. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Percutaneous Image-Guided Breast Biopsy Under This Policy
The policy data provided for this modification does not include a specific code list. The CMS policy document did not supply CPT, HCPCS, or ICD-10 codes in the data available for this post.
Do not assume any code is covered based on this post alone. Pull the full policy text from CMS and identify the exact procedure codes listed before billing under this policy after May 15, 2026.
For reference, percutaneous image-guided breast biopsy procedures commonly involve CPT codes in the breast biopsy and imaging guidance families — but because the actual policy document did not list specific codes, stating those codes here as confirmed covered codes would be inaccurate. Your coding team should pull the current CMS coverage document and cross-reference the procedure codes your practice uses against the covered indications listed in the updated policy.
If you're working with a billing consultant or your MAC's provider outreach team, ask them specifically: "Which CPT codes are listed in the updated CMS percutaneous image-guided breast biopsy coverage policy effective May 15, 2026, and have any codes been added or removed from the covered list?"
That question — asked directly and in writing — protects you if there's a future audit.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.